Table 4.

Response definition after treatment for patients with CLL, using the parameters of Tables 1 and 3

Parameter	CR	PR	PD	SD
Group A
Lymphadenopathy*	None more than 1.5 cm	Decrease ≥ 50%	Increase ≥ 50%	Change of −49% to +49%
Liver and/or spleen size	Normal size	Decrease ≥ 50%	Increase ≥ 50%	Change of −49% to +49%
Constitutional symptoms	None	Any	Any	Any
Polymorphonuclear leukocytes	>1500/μL	>1500/μL or > 50% improvement over baseline	Any	Any
Circulating clonal B lymphocytes	None	Decrease ≥ 50% from baseline	Increase ≥ 50% over baseline	Change of −49% to +49%
Group B
Platelet count	>100 000/μL	>100 000/μL or increase ≥ 50% over baseline	Decrease of ≥ 50% from baseline secondary to CLL	Change of −49 to +49%
Hemoglobin	>11.0 g/dL (untransfused and without erythropoietin)	>11 g/dL or increase ≥ 50% over baseline	Decrease of >2 g/dL from baseline secondary to CLL	Increase ≤11.0 g/dL or <50% over baseline, or decrease <2 g/dL
Marrow	Normocellular, <30% lymphocytes, no B-lymphoid nodules; hypocellular marrow defines CRi	≥ 30% lymphocytes, or B-lymphoid nodules, or not done	Increase of lymphocytes to more than 30% from normal	No change in marrow infiltrate

Values in SI units for leukocytes are 1.5 × 10⁹/L; for platelets 100 × 10⁹/L; and for hemoglobin 110 g/L and 20 g/L.

CR indicates complete remission (all of the criteria have to be met); PR, partial remission (at least one of the criteria of group A and one of the criteria of group B have to be met); PD, progressive disease (at least one of the criteria of group A or one of the criteria of group B have to be met); SD, stable disease (all of the above criteria have to be met).

^*Sum of the products of multiple lymph nodes (as evaluated by CT scans in clinical trials, or by physical examination or ultrasound in general practice).